GSK (NYSE: GSK) has agreed to buy Nuvalent (NASDAQ: NUVL) for $10.6 billion in cash, giving the U.K. drugmaker access to two late-stage lung cancer treatments now under U.S. regulatory review.
The transaction would add neladalkib and zidesamtinib to GSK’s oncology portfolio. GSK said the two therapies have blockbuster potential and could launch this year if approved by the U.S. Food and Drug Administration. Nuvalent focuses on targeted cancer medicines for genetically defined patient groups. Its pipeline includes treatments for forms of non-small cell lung cancer linked to specific mutations, along with an early-stage medicine and multiple preclinical programs.
The all-cash offer values Nuvalent at about $124 per share, according to a GSK filing Tuesday. That represents a 40% premium to Nuvalent’s prior closing price.Nuvalent shares rose 39% in U.S. premarket trading following the announcement. GSK shares declined 2.6% in London.
Neladalkib is under FDA review, with a regulatory decision deadline of Nov. 27. Nuvalent has also submitted zidesamtinib for patients with ROS1-positive non-small cell lung cancer. GSK said the acquisition does not change its 2026 full-year guidance for core operating profit or core earnings-per-share growth. The company expects the transaction to contribute to revenue growth beginning in 2027.
Chief Executive Luke Miels said the deal gives GSK “immediate new sales growth opportunities” and could provide additional treatment options for patients with two forms of non-small cell lung cancer if the lead therapies receive approval.
The transaction comes as GSK works to strengthen its pipeline ahead of expected revenue pressure from the loss of exclusivity for its HIV medicines beginning in 2028. Barclays analysts said the acquisition adds clinically advanced oncology assets and could help offset that HIV-related headwind, while also questioning whether the two lead drugs can reach “mega blockbuster” status.
Analysts at CGS International estimated in January that neladalkib and zidesamtinib could produce combined annual revenue of $823 million in fiscal 2029 if approved.
The Nuvalent acquisition would be GSK’s second-largest transaction, behind its 2014 asset swap with Novartis (NYSE: NVS), in which GSK took control of Novartis’ vaccines business in a deal valued at $20 billion.
The size of the acquisition also represents a shift from GSK’s recent focus on smaller transactions. Miels, who took over from Emma Walmsley at the start of the year, told investors in February that the company would focus on deals in the £2 billion to £4 billion range.
About GSK
GSK plc (NYSE: GSK) is a U.K.-based pharmaceutical and biotechnology company headquartered in London. The company develops and markets vaccines, specialty medicines and general medicines across therapeutic areas including infectious diseases, oncology, respiratory and immunology.
About Nuvalent
Nuvalent Inc. (NASDAQ: NUVL) is a U.S.-based biotechnology company focused on developing targeted therapies for cancer patients. The company’s pipeline includes treatments for genetically defined forms of non-small cell lung cancer.
At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.
Did you find this insightful?
Bad
Just Okay
Amazing
Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer
